Cargando…
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis [Image: see text] ()
BACKGROUND: Standard management in the UK for high-risk stage 1 nonseminoma germ cell tumours of the testis (NSGCTT) is two cycles of adjuvant bleomycin, etoposide (360 mg/m(2)), and cisplatin (BE(360)P) chemotherapy, or surveillance. OBJECTIVE: To test whether one cycle of BE(500)P achieves similar...
Autores principales: | Cullen, Michael, Huddart, Robert, Joffe, Johnathan, Gardiner, Deborah, Maynard, Lauren, Hutton, Paul, Mazhar, Danish, Shamash, Jonathan, Wheater, Matthew, White, Jeff, Goubar, Aicha, Porta, Nuria, Witts, Stephanie, Lewis, Rebecca, Hall, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026695/ https://www.ncbi.nlm.nih.gov/pubmed/31901440 http://dx.doi.org/10.1016/j.eururo.2019.11.022 |
Ejemplares similares
-
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
por: Cafferty, Fay H., et al.
Publicado: (2020) -
Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK
por: Watson, Robert A., et al.
Publicado: (2018) -
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis
por: Bilen, Mehmet Asim, et al.
Publicado: (2016) -
Management options for stage 1 nonseminomatous germ cell tumors of the testis
por: Beck, Stephen D. W.
Publicado: (2010) -
Incidental detection of Zinner syndrome in a patient with nonseminomatous germ cell tumor of testis
por: Khoda, Jeevitesh, et al.
Publicado: (2020)